Germany’s biotech sector grows despite financial crisis


Berlin – Despite the financial crisis, the German biotech sector has grown moderately in 2008: turnover was again above EUR2bn (+9%) and expenditure for R&D rose above EUR1bn (+1.1%). While the number of dedicated biotech companies, remained about the same at 501, there was a slight increase in the number of employees. These are the main results of the company survey conducted by the information platform on behalf of the Federal Ministry of Education and Research (BMBF). The "Biotechnology Company Survey 2009" was officially introduced on May 6th. The data of this comprehensive annual survey were collected along the guidelines of the Organisation for Economic Co-operation and Development (OECD) and present an overview of the German biotech landscape.
Peter Heinrich, spokesman of the BIO Germany management board, emphasised, that in light of the current situation, by international comparison the German biotech sector is still looking relatively good. In the next three years, the industry will need at least one billion euros of equity to follow through with projects currently in company pipelines, finance innovative start-ups, and not be left behind internationally. "We welcome the Federal Ministry of Finance´s initiative to take back parts of the business tax reform", said Peter Heinrich.
The consultancy Ernst&Young released the results of their own assessment of the biotech sector at the same time as The "Biotechnology-Report 2009" confirms the trends elucidated by regarding turnover and the number of employees. However, Ernst&Young only includes about 400 companies in their survey due to a non-OECD biotechnology definition. According to the report, the number of candidates in drug development from German biotech companies has slightly increased from 303 to 308. There are some more drug candidates, 139, in clinical trials Phases I to III as in the previous year with 129. Currently, there are five candidates awaiting approval – compared to seven last year. The decrease is also a result of the successful authorisation of three new drugs.



Leverkusen - Bayer Pharma has a lucky streak. The pharma division of the German chemical giant announced positive Phase III results from regorafenib in colorectal cancer. “We are extremely encouraged by the result of this...



Leverkusen - A short statement from the European Medicines Agency (EMA) and a big step for the German biotech Biofrontera. The agency issued a favourable opinion on Biofrontera's marketing approval application for its drug for...



Leverkusen/San Francisco - Bayer HealthCare and Onyx Pharmaceuticals will not to court over Nevaxar. The two companies reached an agreement related to regorafenib, a late-stage oncology compound. Regorafenib is an oral...



Ingelheim/Ridgefield –Boehringer Ingelheim’s COPD treatment Combivent Respimat has been approved by the U.S. Food and Drug Administration (FDA) for the US market. The new, propellant-free inhaler product for the beta adrenergic...



Rostock – German researchers say overexpression of one of the 49 transport proteins that shuttle substances over the blood-brain barrier could be the key to treating Alzheimer’s disease. In mice, the group headed by Jens Pahnke...



Rehovot/Monheim – Bayer Crop Science may be a step closer to introducing desirable traits in wheat. In the collaboration with Israeli Evogene Ltd. the German company has reached a milestone. Utilising Evogene‘s proprietary...



Willich – Brasilian biopolymer producer Braskem and German bioplastics compounding specialist FKuR GmbH, have signed a compounding agreement for green polyethylene. The tailor-made product will be a first in Europe, according...



Leverkusen - It was a black Tuesday for Bayer. After rumours were leaked out that the FDA has doubts over the German pharmaceutical company's potential blockbuster Xarelto, the shares temporarily dropped as much as 17 percent....



Bad Homburg - German VC firm Creathor venture announced the first closing of its Creathor Venture Fund III. Now, the company is poised to mete out €51million of fresh capital to start-ups. Life science companies will be among the...

Displaying results 21 to 30 out of 454

< Previous 21-30 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • ZEALAND PHARMA (DK)131.00 DKK10.08%
  • DIAMYD MEDICAL -B- (S)4.69 SEK8.56%
  • IPSEN (F)59.44 EUR6.68%


  • MOLOGEN (D)2.05 EUR-10.87%
  • PHARMING (NL)0.22 EUR-8.33%
  • VALNEVA (F)2.40 EUR-4.38%


  • PROTHENA PLC (IE)55.41 USD58.5%
  • VERNALIS (UK)44.50 GBP31.9%
  • E-THERAPEUTICS (UK)13.50 GBP31.7%


  • MOLOGEN (D)2.05 EUR-30.3%
  • SANTHERA (CH)55.00 CHF-28.5%
  • EVOCUTIS (UK)0.04 GBP-20.0%


  • KARO BIO (S)31.20 SEK1850.0%
  • NICOX (F)10.49 EUR473.2%
  • SAREUM HOLDINGS (UK)0.77 GBP234.8%


  • BB BIOTECH (D)44.84 EUR-84.6%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 29.07.2016


All Events